Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?
Sandip BasuRahul V ParghaneSharmila BanerjeePublished in: European journal of nuclear medicine and molecular imaging (2019)